NASDAQ:CDMO Avid Bioservices Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Avid Bioservices, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $15.33 +0.07 (+0.46%) (As of 07/1/2022 12:00 AM ET) Add Compare Share Today's Range$14.84▼$15.7250-Day Range$11.63▼$16.7552-Week Range$11.30▼$34.51Volume476,142 shsAverage Volume626,925 shsMarket Capitalization$946.54 millionP/E Ratio95.82Dividend YieldN/APrice Target$27.00 ProfileAnalyst RatingsChartCompetitorsDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Avid Bioservices Stock Forecast (MarketRank)Analyst RatingBuy3.00 Rating ScoreUpside/Downside74.0% Upside$26.67 Price TargetShort InterestBearish10.78% of Float Sold ShortDividend StrengthN/ASustainability-0.96Upright™ Environmental ScoreNews Sentiment0.36Based on 20 Articles This WeekInsider TradingSelling Shares$235.43 K Sold Last QuarterProj. Earnings Growth22.22%From $0.18 to $0.22 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.2.54 out of 5 starsMedical Sector161st out of 1,429 stocksPharmaceutical Preparations Industry56th out of 682 stocks 3.5 Analyst's Opinion Consensus RatingAvid Bioservices has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $26.67, Avid Bioservices has a forecasted upside of 74.0% from its current price of $15.33.Amount of Analyst CoverageAvid Bioservices has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted10.78% of the float of Avid Bioservices has been sold short.Short Interest Ratio / Days to CoverAvid Bioservices has a short interest ratio ("days to cover") of 9.2.Change versus previous monthShort interest in Avid Bioservices has recently decreased by 0.84%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAvid Bioservices does not currently pay a dividend.Dividend GrowthAvid Bioservices does not have a long track record of dividend growth. Previous Next 3.8 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAvid Bioservices has received a 68.99% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Biopharmaceuticals", "Clinical research services", and "Process engineering services for the pharmaceutical industry" products. See details.Environmental SustainabilityThe Environmental Impact score for Avid Bioservices is -0.96. Previous Next 2.4 News and Social Media Coverage News SentimentAvid Bioservices has a news sentiment score of 0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 20 news articles for Avid Bioservices this week, compared to 1 article on an average week.Search Interest8 people have searched for CDMO on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Avid Bioservices insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $235,429.00 in company stock.Percentage Held by InsidersOnly 1.49% of the stock of Avid Bioservices is held by insiders.Percentage Held by Institutions99.36% of the stock of Avid Bioservices is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Avid Bioservices are expected to grow by 22.22% in the coming year, from $0.18 to $0.22 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Avid Bioservices is 95.82, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 47.10.Price to Earnings Ratio vs. SectorThe P/E ratio of Avid Bioservices is 95.82, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 42.02.Price to Book Value per Share RatioAvid Bioservices has a P/B Ratio of 11.98. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive CDMO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Avid Bioservices and its competitors with MarketBeat's FREE daily newsletter. Email Address About Avid Bioservices (NASDAQ:CDMO)Avid Bioservices, Inc., a contract development and manufacturing organization, provides process development and current good manufacturing practices (CGMP) clinical and commercial manufacturing services focused on biopharmaceutical drug substances derived from mammalian cell culture. It produces monoclonal antibodies and recombinant proteins; and offers services, including CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, and regulatory submission and support. The company also provides various process development services, such as upstream and downstream development and optimization, analytical methods development, testing, and characterization. It serves biotechnology and pharmaceutical companies. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was incorporated in 1981 and is headquartered in Tustin, California.Read More CDMO Stock News HeadlinesJune 30, 2022 | finance.yahoo.comRead How Avid Bioservices Fared In Q4June 30, 2022 | americanbankingnews.comAvid Bioservices (NASDAQ:CDMO) Shares Down 2.1% on Insider SellingJune 30, 2022 | americanbankingnews.comAvid Bioservices (NASDAQ:CDMO) Stock Price Down 2.1% After Insider SellingJune 30, 2022 | americanbankingnews.comRichard B. Hancock Sells 2,463 Shares of Avid Bioservices, Inc. (NASDAQ:CDMO) StockJune 30, 2022 | fool.comAvid Bioservices, Inc. (CDMO) Q4 2022 Earnings Call TranscriptJune 29, 2022 | finance.yahoo.comAvid Bioservices Reports Financial Results for Fourth Quarter and Full Fiscal Year Ended April 30, 2022 and Recent DevelopmentsJune 29, 2022 | americanbankingnews.comAvid Bioservices, Inc. (NASDAQ:CDMO) Director Richard B. Hancock Sells 7,537 Shares of StockJune 28, 2022 | benzinga.comAvid Bioservices's Earnings OutlookJune 28, 2022 | americanbankingnews.comAvid Bioservices (CDMO) Scheduled to Post Quarterly Earnings on WednesdayJune 22, 2022 | finance.yahoo.comAvid Bioservices to Report Financial Results for Quarter and Fiscal Year Ended April 30, 2022 After Market Close on June 29, 2022June 22, 2022 | americanbankingnews.comAvid Bioservices, Inc. (NASDAQ:CDMO) Given Consensus Recommendation of "Moderate Buy" by BrokeragesJune 14, 2022 | seekingalpha.comAvid Bioservices launches analytical and process development labsJune 14, 2022 | finance.yahoo.comAvid Bioservices Announces Launch of Analytical and Process Development Suites Within New, World-Class Viral Vector Development and Manufacturing FacilitySee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CDMO CUSIPN/A CIK704562 Webwww.avidbio.com Phone(714) 508-6100Fax714-838-5817Employees252Year FoundedN/ACompany Calendar Last Earnings12/07/2021Today7/01/2022Next Earnings (Estimated)9/14/2022Fiscal Year End4/30/2023Price Target and Rating Average Stock Price Forecast$26.67 High Stock Price Forecast$30.00 Low Stock Price Forecast$22.00 Forecasted Upside/Downside+76.1%Consensus RatingBuy Rating Score (0-4)3 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)$0.159990 Trailing P/E Ratio95.82 Forward P/E Ratio85.17 P/E GrowthN/ANet Income$11.21 million Net Margins12.13% Pretax Margin12.13% Return on Equity27.58% Return on Assets5.51% Debt Debt-to-Equity Ratio2.50 Current Ratio2.63 Quick Ratio2.36 Sales & Book Value Annual Sales$95.87 million Price / Sales9.87 Cash Flow$0.25 per share Price / Cash Flow60.94 Book Value$1.28 per share Price / Book11.98Miscellaneous Outstanding Shares61,744,000Free Float60,824,000Market Cap$946.54 million OptionableOptionable Beta2.31 Avid Bioservices Frequently Asked Questions Should I buy or sell Avid Bioservices stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Avid Bioservices in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Avid Bioservices stock. View analyst ratings for Avid Bioservices or view top-rated stocks. What is Avid Bioservices' stock price forecast for 2022? 3 Wall Street research analysts have issued twelve-month price objectives for Avid Bioservices' shares. Their CDMO stock forecasts range from $22.00 to $30.00. On average, they anticipate Avid Bioservices' stock price to reach $26.67 in the next year. This suggests a possible upside of 74.0% from the stock's current price. View analysts' price targets for Avid Bioservices or view top-rated stocks among Wall Street analysts. How has Avid Bioservices' stock price performed in 2022? Avid Bioservices' stock was trading at $29.18 at the start of the year. Since then, CDMO shares have decreased by 47.5% and is now trading at $15.33. View the best growth stocks for 2022 here. When is Avid Bioservices' next earnings date? Avid Bioservices is scheduled to release its next quarterly earnings announcement on Wednesday, September 14th 2022. View our earnings forecast for Avid Bioservices. How were Avid Bioservices' earnings last quarter? Avid Bioservices, Inc. (NASDAQ:CDMO) posted its earnings results on Tuesday, December, 7th. The biopharmaceutical company reported $0.06 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.02 by $0.04. The biopharmaceutical company had revenue of $26.11 million for the quarter, compared to analysts' expectations of $25 million. Avid Bioservices had a trailing twelve-month return on equity of 27.58% and a net margin of 12.13%. During the same quarter in the previous year, the firm earned $0.01 earnings per share. View Avid Bioservices' earnings history. When did Avid Bioservices' stock split? How did Avid Bioservices' stock split work? Shares of Avid Bioservices reverse split on the morning of Monday, July 10th 2017. The 1-7 reverse split was announced on Friday, July 7th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, July 7th 2017. An investor that had 100 shares of Avid Bioservices stock prior to the reverse split would have 14 shares after the split. What guidance has Avid Bioservices issued on next quarter's earnings? Avid Bioservices issued an update on its FY 2023 earnings guidance on Wednesday, June, 29th. The company provided EPS guidance of for the period. The company issued revenue guidance of $140.00 million-$145.00 million, compared to the consensus revenue estimate of $146.50 million. Who are Avid Bioservices' key executives? Avid Bioservices' management team includes the following people: Mr. Nicholas Stewart Green B.Sc., MBA, Pres, CEO & Director (Age 57, Pay $1.55M) (LinkedIn Profile)Mr. Daniel R. Hart, Chief Financial Officer (Age 49, Pay $899.28k) (LinkedIn Profile)Mr. Mark R. Ziebell J.D., VP, Gen. Counsel & Corp. Sec. (Age 58, Pay $707.75k) (LinkedIn Profile)Mr. Richard Richieri, Chief Operations Officer (Age 57)Ms. Lorna Larson, Sr. Director of HRMr. Matthew Kwietniak, Chief Commercial OfficerDr. Shelley P. M. Fussey, VP of Intellectual Property (Age 56)Ms. Tracy L. Kinjerski, VP of Bus. OperationsDr. Harold F. Dvorak, Medical & Scientific AdvisorProf. Alan J. Schroit, Medical & Scientific Advisor What is Roger Lias' approval rating as Avid Bioservices' CEO? 2 employees have rated Avid Bioservices CEO Roger Lias on Glassdoor.com. Roger Lias has an approval rating of 49% among Avid Bioservices' employees. This puts Roger Lias in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. Who are some of Avid Bioservices' key competitors? Some companies that are related to Avid Bioservices include Zai Lab (ZLAB), Karuna Therapeutics (KRTX), Turning Point Therapeutics (TPTX), Galapagos (GLPG), Cytokinetics (CYTK), Bausch Health Companies (BHC), Harmony Biosciences (HRMY), AbCellera Biologics (ABCL), Amicus Therapeutics (FOLD), Prestige Consumer Healthcare (PBH), PTC Therapeutics (PTCT), Blueprint Medicines (BPMC), Corcept Therapeutics (CORT), CureVac (CVAC) and Indivior (INVVY). View all of CDMO's competitors. What other stocks do shareholders of Avid Bioservices own? Based on aggregate information from My MarketBeat watchlists, some companies that other Avid Bioservices investors own include Array Technologies (ARRY), Anavex Life Sciences (AVXL), Inovio Pharmaceuticals (INO), Advanced Micro Devices (AMD), Dynavax Technologies (DVAX), Micron Technology (MU), QUALCOMM (QCOM), NVIDIA (NVDA), Novavax (NVAX) and Pfizer (PFE). What is Avid Bioservices' stock symbol? Avid Bioservices trades on the NASDAQ under the ticker symbol "CDMO." How do I buy shares of Avid Bioservices? Shares of CDMO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Avid Bioservices' stock price today? One share of CDMO stock can currently be purchased for approximately $15.33. How much money does Avid Bioservices make? Avid Bioservices (NASDAQ:CDMO) has a market capitalization of $946.54 million and generates $95.87 million in revenue each year. The biopharmaceutical company earns $11.21 million in net income (profit) each year or $0.159990 on an earnings per share basis. How many employees does Avid Bioservices have? Avid Bioservices employs 252 workers across the globe. How can I contact Avid Bioservices? Avid Bioservices' mailing address is 2642 Michelle Drive Suite 200, TUSTIN CA, 92780. The official website for Avid Bioservices is www.avidbio.com. The biopharmaceutical company can be reached via phone at (714) 508-6100, via email at [email protected], or via fax at 714-838-5817. This page (NASDAQ:CDMO) was last updated on 7/2/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here